GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Renal | AB, BC, ON | Recruiting
AV-951-20-304
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals
Start Date: September 9, 2021

NCT #: NCT04987203

SPONSOR: AVEO Pharmaceuticals in collaboration with Parexel and BMS

INFO: https://clinicaltrials.gov/ct2/show/NCT04987203?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=5

CONTACT: 857-400-0101

Bladder | AB, ON, QC | Recruiting
CA102-003
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
Start Date: August 29, 2021

NCT #: NCT04943900

SPONSOR: Bristol-Myers Squibb

INFOhttps://clinicaltrials.gov/ct2/show/NCT04943900?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=14

CONTACT:  855-907-3286

OTHER CANADIAN CENTRES:

1. Mount Sinai Hospital (Toronto)
2. Centre recherche CHUM (Montreal)
3. Cross Cancer institute (Edmonton)

Prostate | ON | Recruiting
PRIAPUS
Potency preservation in prostate cancer patients treated with ultra sound-guided low-dose rate brachytherapy
Dr. Lucas Mendez
Start Date: June 27, 2021

NCT #: NCT04718987

SPONSOR: Lawson Health Research Institute 

INFO:  https://clinicaltrials.gov/ct2/show/NCT04718987

CONTACT:  519-685-8500 ext 54005

Renal, Bladder | AB, BC, ON, QC | Recruiting
CA052-002
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Start Date: May 27, 2021

NCT #: NCT04895709

SPONSORBristol-Myers Squibb

INFO: https://clinicaltrials.gov/study/NCT04895709

CONTACT: Paul.Toren@crchudequebec.ulaval.ca (CHUQ)  

Other Canadian Centres:

The Ottawa Hospital Cancer Centre (Ottawa)        

Cross Cancer Centre (Edmonton)          

BC Vancouver (Vancouver)        

Juravinski Cancer Centre (Hamilton)    

Princess Margaret Cancer Centre (Toronto)        

Centre hospitalier de l'Université de Montréal (Montreal)

Renal | ON | Recruiting
ABILITY
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Apollomics Inc.
Start Date: April 27, 2021

NCT #:  NCT05086692

SPONSOR: Medicenna Therapeutics

INFO:   https://clinicaltrials.gov/ct2/show/NCT05086692?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=26

CONTACT:  604-340-3081

OTHER CANADIAN CENTRES: Princess Margaret Cancer Centre (Toronto)         

 

Renal | AB, BC, ON, QC | Recruiting
MK-6482-012
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Merck Sharp & Dohme LLC
Start Date: April 14, 2021

NCT #: NCT04736706

SPONSOR: Merck Sharp & Dohme LLC & Eisai

INFOhttps://clinicaltrials.gov/ct2/show/NCT04736706?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=11

CONTACT:  1-888-577-8839

OTHER CANADIAN CENTRES: 

Tom Baker Cancer Centre (Calgary): Contact 403-521-3266.                
BC Cancer - Vancouver Center (Vancouver): Contact 604-877-6000         
Juravinski Cancer Centre (Hamilton): Contact 905-387-9495 x 63123            
Sunnybrook Research Institute (Toronto): Contact: 416-480-5847            
CHU de Quebec Universite Laval (Quebec City): 418-525-4444
 

Prostate | BC, ON | Recruiting
GUNS
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS)
Dr. Martin E. Gleave
Start Date: March 21, 2021

NCT #: NCT04812366

SPONSOR: University of British Columbia in collaboration with Janssen Inc. UHN, Toronto.

INFOhttps://classic.clinicaltrials.gov/ct2/show/NCT04812366

CONTACT

Jonathan Ma (BC): jma@prostatecentre.com                      
Anuja Parikh (UHN): Anuja.Parikh@uhn.ca 

OTHER CANADIAN CENTRES:

1. Vancouver Prostate Centre

2. University Health Network

Renal | QC | Recruiting
MK-6482-011
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Merck Sharp & Dohme LLC
Start Date: February 25, 2021

NCT #: NCT04586231

SPONSOR: Merck Sharp & Dohme LLC & Eisai

INFOhttps://clinicaltrials.gov/ct2/show/NCT04586231?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=13

CONTACT:

CISSS de la Monteregie-Centre: Greenfield Park, Quebec
Contact: 450-466-5000 x 3226
                                                             
CHU de Quebec Universite Laval: Quebec City, Quebec                                 
 418-525-4444 x 67712
                                                           
CHUS - Centre Hosp. Univ. Sherbrooke: Sherbrooke, Quebec                      
819-346-1110 x 12811                                                   
 

OTHER CANADIAN CENTRES: 

Greenfield Park, Quebec 

Quebec City, Quebec

Sherbrooke, Quebec

Bladder | ON | Recruiting
NAUTICAL
Neoadjuvant Upper Tract Invasive Cancer Trial
Dr. Girish Kulkarni
Start Date: February 8, 2021

NCT #: NCT04574960

SPONSOR: UHN in collaboration with Bladder Cancer Canada

INFOhttps://clinicaltrials.gov/ct2/show/NCT04574960?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=1

CONTACT:  Sarah Cheung (437) 335-2949

Prostate | ON | Recruiting
IGPC-5
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy (IGPC-5)
Dr. Glen Bauman
Start Date: February 4, 2021

NCT #: NCT04053842

SPONSOR: London Health Sciences Centre

INFO: https://clinicaltrials.gov/ct2/show/NCT04053842

CONTACT: Catherine Hildebrand // 519-685-8500 ext 53535